CA1270438A - Vaccin contre l'influenza - Google Patents

Vaccin contre l'influenza

Info

Publication number: CA1270438A
Authority: CA; Canada
Prior art keywords: nucleoprotein; virus; influenza virus; human; animal body
Prior art date: 1985-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000500552A

Other languages

English (en)

Inventor

Brigitte A. Askonas

David C. Wraith

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medical Research Council

Original Assignee

Medical Research Council

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-01-28

Filing date

1986-01-28

Publication date

1990-06-19

1986-01-28 Application filed by Medical Research Council filed Critical Medical Research Council

1990-06-19 Application granted granted Critical

1990-06-19 Publication of CA1270438A publication Critical patent/CA1270438A/fr

Status Expired legal-status Critical Current

Links

229960003971 influenza vaccine Drugs 0.000 title abstract description 5
102000011931 Nucleoproteins Human genes 0.000 claims abstract description 83
108010061100 Nucleoproteins Proteins 0.000 claims abstract description 83
241000700605 Viruses Species 0.000 claims abstract description 64
239000000463 material Substances 0.000 claims abstract description 34
241000712461 unidentified influenza virus Species 0.000 claims abstract description 31
208000015181 infectious disease Diseases 0.000 claims abstract description 19
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 15
239000003599 detergent Substances 0.000 claims abstract description 11
230000001939 inductive effect Effects 0.000 claims abstract description 10
230000002458 infectious effect Effects 0.000 claims abstract description 8
239000004365 Protease Substances 0.000 claims abstract description 7
238000007911 parenteral administration Methods 0.000 claims abstract description 6
241000124008 Mammalia Species 0.000 claims abstract description 5
108091005804 Peptidases Proteins 0.000 claims abstract 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 4
238000000034 method Methods 0.000 claims description 43
102000005348 Neuraminidase Human genes 0.000 claims description 13
108010006232 Neuraminidase Proteins 0.000 claims description 13
241001465754 Metazoa Species 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
229940009976 deoxycholate Drugs 0.000 claims description 7
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
108060003393 Granulin Proteins 0.000 claims description 5
229920001184 polypeptide Polymers 0.000 claims description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 5
102000004196 processed proteins & peptides Human genes 0.000 claims description 5
108010004032 Bromelains Proteins 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
230000014509 gene expression Effects 0.000 claims description 4
102000004169 proteins and genes Human genes 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
239000006228 supernatant Substances 0.000 claims description 4
125000003275 alpha amino acid group Chemical group 0.000 claims description 3
235000019835 bromelain Nutrition 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
230000003612 virological effect Effects 0.000 claims description 3
239000008188 pellet Substances 0.000 claims description 2
239000000047 product Substances 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
238000003745 diagnosis Methods 0.000 claims 4
239000004094 surface-active agent Substances 0.000 claims 4
238000001356 surgical procedure Methods 0.000 claims 4
238000002560 therapeutic procedure Methods 0.000 claims 4
235000019419 proteases Nutrition 0.000 claims 3
230000001954 sterilising effect Effects 0.000 claims 2
125000002091 cationic group Chemical group 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
238000013467 fragmentation Methods 0.000 abstract 1
238000006062 fragmentation reaction Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 27
241000699670 Mus sp. Species 0.000 description 18
229960005486 vaccine Drugs 0.000 description 13
238000007920 subcutaneous administration Methods 0.000 description 10
206010022000 influenza Diseases 0.000 description 7
241000712431 Influenza A virus Species 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
210000004989 spleen cell Anatomy 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
101710085938 Matrix protein Proteins 0.000 description 4
101710127721 Membrane protein Proteins 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000037452 priming Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
229940031626 subunit vaccine Drugs 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
231100000518 lethal Toxicity 0.000 description 3
230000001665 lethal effect Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 2
101150118742 NP gene Proteins 0.000 description 2
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000713196 Influenza B virus Species 0.000 description 1
241000713297 Influenza C virus Species 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000001492 haemagglutinating effect Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003071 memory t lymphocyte Anatomy 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
244000144977 poultry Species 0.000 description 1
235000013594 poultry meat Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA000500552A 1985-01-28 1986-01-28 Vaccin contre l'influenza Expired CA1270438A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8502096		1985-01-28
GB858502096A GB8502096D0 (en)	1985-01-28	1985-01-28	Influenza vaccine

Publications (1)

Publication Number	Publication Date
CA1270438A true CA1270438A (fr)	1990-06-19

Family

ID=10573520

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000500552A Expired CA1270438A (fr)	1985-01-28	1986-01-28	Vaccin contre l'influenza

Country Status (5)

Country	Link
EP (1)	EP0211029A1 (fr)
JP (1)	JPS62501973A (fr)
CA (1)	CA1270438A (fr)
GB (1)	GB8502096D0 (fr)
WO (1)	WO1986004242A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2671974A1 (fr) *	1991-01-24	1992-07-31	Pasteur Merieux Serums Vacc	Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.
US5741493A (en) *	1991-01-24	1998-04-21	Pasteur Merieux Serums Et Vaccins	Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
AT501883B1 (de) *	2005-09-12	2006-12-15	Weninger Ges M B H	Selbsttätige einrichtung zur bewässerung von kulturpflanzen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU405949B1 (en) *	1966-02-24	1970-09-18	The Australian National University	Influenza virus sub-unit vaccine
FR2483779A1 (fr) *	1980-06-05	1981-12-11	Synthelabo	Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins

1985
- 1985-01-28 GB GB858502096A patent/GB8502096D0/en active Pending
1986
- 1986-01-23 EP EP86900813A patent/EP0211029A1/fr not_active Withdrawn
- 1986-01-23 WO PCT/GB1986/000044 patent/WO1986004242A1/fr not_active Ceased
- 1986-01-23 JP JP61500850A patent/JPS62501973A/ja active Pending
- 1986-01-28 CA CA000500552A patent/CA1270438A/fr not_active Expired

Also Published As

Publication number	Publication date
JPS62501973A (ja)	1987-08-06
WO1986004242A1 (fr)	1986-07-31
EP0211029A1 (fr)	1987-02-25
GB8502096D0 (en)	1985-02-27

Legal Events

Date	Code	Title	Description
1992-12-21	MKLA	Lapsed

Publication	Publication Date	Title
KR100927517B1 (ko)	2009-11-17	생균 백신
KR100703571B1 (ko)	2007-04-05	인플루엔자에 대한 펩티드-기초 백신
Yap et al.	1978	The recovery of mice from influenza virus infection: adoptive transfer of immunity with immune T lymphocytes
Prehaud et al.	1989	Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors
US4317811A (en)	1982-03-02	Herpes simplex type 1 subunit vaccine
US5766601A (en)	1998-06-16	Cross-reactive influenza a immunization
EP2976357B1 (fr)	2018-10-17	Vaccins de la nucléoprotéine du virus grippal
Yamada et al.	1985	Influenza virus hemagglutinin-specific cytotoxic T cell response induced by polypeptide produced in Escherichia coli.
Russell et al.	1980	Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of the virion
CN111481663B (zh)	2022-12-09	一种流感病毒活疫苗及其制备方法
CN117815377A (zh)	2024-04-05	mRNA的用途
Hocart et al.	1995	Preparation and characterization of a purified influenza virus neuraminidase vaccine
Virelizier et al.	1976	The role of humoral immunity in host defence against influenza A infection in mice
WO1986004242A1 (fr)	1986-07-31	Ameliorations relatives au vaccin antigrippe
JPS6169731A (ja)	1986-04-10	ワクチン用ポリペプチド
CA1152895A (fr)	1983-08-30	Procede pour preparer de nouvelles souches de virus de la grippe et des vaccins les renfermant
PL93689B1 (fr)	1977-06-30
KR102365039B1 (ko)	2022-02-18	부유세포 배양에 적응된 A/ASIA/Sea-97 유전형 구제역 바이러스 백신주 및 이의 제조방법
EP3560511A2 (fr)	2019-10-30	Composition immunogène
WO1994021798A1 (fr)	1994-09-29	Stimulation d'une reponse immunitaire par une proteine virale
EP0542895B1 (fr)	1996-11-20	Immunisation a reaction croisee contre la grippe a
KR102211077B1 (ko)	2021-02-02	바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
CN105497890A (zh)	2016-04-20	一枝蒿多糖作为疫苗佐剂的应用
US4540669A (en)	1985-09-10	Herpes simplex type I subunit vaccine
Rudometova et al.	2026	Intranasal Immunization with Recombinant Hemagglutinin of Influenza A/H5 Virus Complexed with Novochizol Induces Virus-Neutralizing Antibodies and Protects Animals from Lethal Viral Challenge